Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reduction-Reference-Cited by-同舟云学术

Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reduction

Published:1991-03 Issue:1 Volume:18 Page:1-19
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Koning J.,Palmer P.,Franks C.R.,Mulder D.E.,Speyer J.L.,Green M.D.,Hellmann K.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference51 articles.

1. A randomized trial of cardioprotection with ICRF-187 in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide (AVL 86-01). Data on file at EuroCetus B.V.

2. Acute toxicity studies in rats and mice. Data on file at EuroCetus B.V.

3. Disposition of cardioprotective agent ICRF-187 in rats;Baldwin;Pharm. Res.,1988

4. Adriamycin chemotherapy efficacy, safety and pharmacologic basis of an intermittent single high-dose schedule;Benjamin;Cancer,1974

5. Heart disease;Braunwald,1988

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer;International Journal of Molecular Sciences;2022-11-13

2. Advances on Chelation and Chelator Metal Complexes in Medicine;International Journal of Molecular Sciences;2020-04-03

3. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology;Expert Opinion on Investigational Drugs;2019-06-21

4. Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions;Journal of Oncology Pharmacy Practice;2013-05-14

5. Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy;Biomedicine & Pharmacotherapy;2012-03